Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046060 | 0.87 | HINT1 (0.53) | ADORA2AADORA3ADORA1ADORA2BNT5E | |
| SCHEMBL13046064 | 0.86 | DNMT1 (0.49) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL10026379 | 0.85 | ADORA3 (0.61) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL13046058 | 0.85 | NT5E (0.61) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL10026396 | 0.85 | ADORA3 (0.61) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL13046068 | 0.83 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL13046059 | 0.82 | ADORA2A (0.44) | ADORA2AADORA3ADORA1ADORA2BLMNA | |
| SCHEMBL14030736 | 0.81 | ADORA3 (0.59) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13449217 | 0.81 | ADORA3 (0.59) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13046062 | 0.77 | ADORA3 (0.33) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | BARRE LOUISA | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | TPMT, NUDT1, DUT | ADORA2A 66/4885ADORA3 92/4885ADORA1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.